CD8A and colon adenocarcinoma: A reduced tumor growth rate and an increased number of infiltrating CD8+ lymphocytes were observed when MC38 colon adenocarcinoma cells were injected into RELT−/− mice in comparison to control mice, indicating that RELT counters the tumor-killing ability of CD8+ cells.